Sumitomo Pharma Co.Ltd.

As of March 31, 2025, Sumitomo Pharma Co.Ltd. carries a market capitalization of 289.62B, placing it among publicly traded companies globally. Its enterprise value stands at 555.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sumitomo Pharma Co.Ltd.'s next confirmed earnings release is scheduled for October 30, 2026.

As of March 31, 2025, Sumitomo Pharma Co.Ltd. has 397.29M shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, Sumitomo Pharma Co.Ltd. maintains a current ratio of 1.05, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2025.

Over the twelve months ended March 31, 2025, Sumitomo Pharma Co.Ltd. recorded an income tax benefit of -20.69B rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, Sumitomo Pharma Co.Ltd.'s stock has gained approximately 11.02% over the past 52 weeks. The 50-day moving average sits at 1,568.77, while the 200-day moving average is 1,811.16.

As of March 31, 2025, Sumitomo Pharma Co.Ltd. holds 39.96B in cash and equivalents against 305.42B in total debt, resulting in a net debt position of 282.31B. Total book value stands at 169.48B, with working capital of 12.57B providing operational flexibility.

These figures cover the twelve months ended March 31, 2025.

Sumitomo Pharma Co.Ltd.'s most recent stock split took place on March 26, 1992 with a 20:21 split ratio.